New Risk • May 22
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 274% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr23m free cash flow). Share price has been highly volatile over the past 3 months (118% average daily change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (274% increase in shares outstanding). Market cap is less than US$10m (€5.44m market cap, or US$6.31m). Duyuru • Apr 27
LifeClean International AB (publ), Annual General Meeting, May 27, 2026 LifeClean International AB (publ), Annual General Meeting, May 27, 2026, at 13:00 W. Europe Standard Time. Location: at born laws premises, strandvagen 7a, stockholm Sweden Duyuru • May 28
LifeClean International AB (publ), Annual General Meeting, Jun 30, 2025 LifeClean International AB (publ), Annual General Meeting, Jun 30, 2025, at 13:00 W. Europe Standard Time. Location: at born advokaters premises, strandvagen 7a, 102 45 stockholm. Sweden Duyuru • Feb 20
LifeClean International AB (publ), Annual General Meeting, Mar 21, 2025 LifeClean International AB (publ), Annual General Meeting, Mar 21, 2025, at 08:00 W. Europe Standard Time. Location: at born advokater`s premises, strandvagen 7a, 102 45, stockholm. Sweden New Risk • Oct 27
New major risk - Revenue and earnings growth Earnings have declined by 39% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (15% average weekly change). Earnings have declined by 39% per year over the past 5 years. Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr43m). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€18.1m market cap, or US$19.5m). Reported Earnings • Oct 25
Third quarter 2024 earnings released Third quarter 2024 results: Revenue: kr14.1m (up 39% from 3Q 2023). Net loss: kr13.3m (loss widened 11% from 3Q 2023). Revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 4.1% growth forecast for the Chemicals industry in Germany. New Risk • Oct 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 12% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-kr8.1m). Minor Risks Less than 1 year of cash runway based on current free cash flow (-kr40m). Currently unprofitable and not forecast to become profitable over next 2 years (kr10m net loss in 2 years). Shareholders have been diluted in the past year (18% increase in shares outstanding). Market cap is less than US$100m (€19.5m market cap, or US$21.6m). Breakeven Date Change • Sep 03
No longer forecast to breakeven The analyst covering LifeClean International no longer expects the company to break even during the foreseeable future. The company was expected to make a profit of kr3.00m in 2026. New forecast suggests the company will make a loss of kr4.00m in 2026. Reported Earnings • Sep 01
Second quarter 2024 earnings released Second quarter 2024 results: Revenue: kr21.0m (up 47% from 2Q 2023). Net loss: kr12.8m (loss widened 21% from 2Q 2023). Revenue is forecast to grow 26% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Chemicals industry in Germany. Reported Earnings • May 08
First quarter 2024 earnings released First quarter 2024 results: Revenue: kr16.0m (up 17% from 1Q 2023). Net loss: kr15.0m (loss widened 95% from 1Q 2023). Revenue is forecast to grow 27% p.a. on average during the next 3 years, compared to a 4.2% growth forecast for the Chemicals industry in Germany. New Risk • Apr 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 6.3% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-kr40m free cash flow). Earnings have declined by 42% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (7.8% average weekly change). Shareholders have been diluted in the past year (6.3% increase in shares outstanding). Revenue is less than US$5m (kr53m revenue, or US$5.0m). Market cap is less than US$100m (€37.6m market cap, or US$40.9m). Reported Earnings • Feb 21
Full year 2023 earnings released: kr0.94 loss per share (vs kr0.83 loss in FY 2022) Full year 2023 results: kr0.94 loss per share (further deteriorated from kr0.83 loss in FY 2022). Revenue: kr53.7m (up 14% from FY 2022). Net loss: kr44.2m (loss widened 23% from FY 2022). Revenue is forecast to grow 23% p.a. on average during the next 2 years, compared to a 2.7% growth forecast for the Chemicals industry in Germany. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings. Board Change • Feb 01
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 2 highly experienced directors. Independent Board Member Petra Sas was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 27
Third quarter 2023 earnings released Third quarter 2023 results: Revenue: kr10.4m (up 17% from 3Q 2022). Net loss: kr11.9m (loss widened 44% from 3Q 2022). Revenue is forecast to grow 33% p.a. on average during the next 3 years, compared to a 3.3% growth forecast for the Chemicals industry in Germany. Reported Earnings • Aug 31
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: kr14.5m (down 2.6% from 2Q 2022). Net loss: kr10.6m (loss widened 46% from 2Q 2022). Revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 2.2% growth forecast for the Chemicals industry in Germany. New Risk • Aug 01
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 9.8% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (9.8% average weekly change). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (kr5.0m net loss in 2 years). Shareholders have been diluted in the past year (9.1% increase in shares outstanding). Revenue is less than US$5m (kr48m revenue, or US$4.5m). Market cap is less than US$100m (€30.0m market cap, or US$32.9m). Reported Earnings • Feb 18
Full year 2022 earnings released: kr0.83 loss per share (vs kr0.83 loss in FY 2021) Full year 2022 results: kr0.83 loss per share (further deteriorated from kr0.83 loss in FY 2021). Revenue: kr48.3m (down 18% from FY 2021). Net loss: kr36.1m (loss widened 1.0% from FY 2021). Revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 1.5% growth forecast for the Chemicals industry in Germany. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Board Member Petra Sas was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Duyuru • Nov 10
LifeClean Develops Revolutionary Method for PFAS Removal LifeClean International AB (publ) ("the Company") announces that the Company has developed an effective method for removing PFAS substances ("PFAS") from fire-fighting foam tanks.PFAS are environmentally and health-damaging substances previously used on a large scale as an ingredient in, e.g., fire-fighting foams. The phase-out of PFAS is ongoing and global, which opens up a significant market potential for the Company. Successful customer tests of LifeClean's method have already been conducted. The LifeClean group, under the leadership of Chairman and founder Ragnar Krefting, has researched, developed, and successfully tested a new method for PFAS removal from contaminated surfaces. The method is adapted for the best effect against PFAS and is part of a new assortment in LifeClean's product range. The new product assortment is based on the Company's patented chlorine dioxide formulation and also includes ingredients from the subsidiary Kempartner. Test results of the LifeClean method at Södertörn's firefighting association of five fire foam tanks have shown positive results where =99.97% of PFAS substances in the tanks have been detached according to an accredited third-party laboratory. In January 2023, the LifeClean-treated tanks would otherwise have been plugged and disposed of following current environmental and waste legislation. Now, this does not need to be done after decontaminating with the LifeClean method, which means a great economic saving of public funds. The same problem exists in the rest of the world, and the Company will, in a first step, process the Nordic market and, in a second step, the rest of the EU. An investigation is underway to see if it is possible to obtain regulatory exemptions for faster sales to countries where additional authorization is required. The company estimates that approx. 75,000 fire trucks in Europe are PFAS-contaminated and in need of decontamination. The estimated revenue per fire truck is approx. SEK 60,000 +/- 20,000, depending on tank size. PFAS are a group of chemicals with unique properties such as heat resistance and have, among other things, been an important ingredient in fire-fighting foams for firefighting at areas such as airports, ships, and defense facilities worldwide. PFAS are very resilient to degradation and are sometimes referred to as "forever chemicals". There is a high global consensus that PFAS should be phased out, even in fire-fighting foams where, among others, the carcinogenic and reproductively toxic substances PFOS and PFOA have been used. Reported Earnings • Nov 06
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: kr9.10m (down 21% from 3Q 2021). Net loss: kr8.31m (loss narrowed 1.3% from 3Q 2021). Revenue is forecast to grow 13% p.a. on average during the next 3 years, while revenues in the Chemicals industry in Germany are expected to remain flat. Board Change • May 03
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Board member Jan Sjowall was the last director to join the board, commencing their role in 2016. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Feb 18
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Full year 2021 results: kr0.78 loss per share (down from kr0.14 loss in FY 2020). Revenue: kr55.3m (up 69% from FY 2020). Net loss: kr32.8m (loss widened kr29.6m from FY 2020). Revenue missed analyst estimates by 52%. Reported Earnings • Nov 10
Third quarter 2021 earnings released The company reported a decent third quarter result with improved revenues, although losses increased and control over costs was weaker. Third quarter 2021 results: Revenue: kr12.1m (up 261% from 3Q 2020). Net loss: kr8.42m (loss widened 271% from 3Q 2020). Reported Earnings • Aug 20
Second quarter 2021 earnings released: kr0.15 loss per share (vs kr0.76 profit in 2Q 2020) The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: kr18.9m (down 3.2% from 2Q 2020). Net loss: kr6.36m (down 215% from profit in 2Q 2020). Breakeven Date Change • Jul 27
Forecast to breakeven in 2021 The analyst covering LifeClean International expects the company to break even for the first time. New forecast suggests the company will make a profit of kr2.00m in 2021. Earnings growth of 101% is required to achieve expected profit on schedule. Reported Earnings • May 06
First quarter 2021 earnings released The company reported a mediocre first quarter result with weaker earnings and weaker control over costs, although revenues improved. First quarter 2021 results: Revenue: kr12.0m (up 88% from 1Q 2020). Net loss: kr6.99m (down kr7.35m from profit in 1Q 2020). Reported Earnings • Feb 21
Full year 2020 earnings released: kr0.14 loss per share The company reported a solid full year result with reduced losses, improved revenues and improved control over expenses. Full year 2020 results: Revenue: kr32.7m (up kr29.0m from FY 2019). Net loss: kr3.20m (loss narrowed 69% from FY 2019). Is New 90 Day High Low • Jan 28
New 90-day low: €0.93 The company is down 11% from its price of €1.05 on 30 October 2020. The German market is up 19% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 28% over the same period.